Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
MacroGenics to Participate in Upcoming Investor Conference
07:00am, Wednesday, 19'th May 2021
ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q1 2021 Results - Earnings Call Transcript
10:40pm, Thursday, 29'th Apr 2021
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q1 2021 Results - Earnings Call Transcript
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
06:47pm, Thursday, 29'th Apr 2021
MacroGenics (MGNX) delivered earnings and revenue surprises of -69.81% and -45.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call
04:30pm, Monday, 19'th Apr 2021
ROCKVILLE, MD, April 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therape
Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy
02:18am, Thursday, 15'th Apr 2021
LUND, Sweden, April 15, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research collaboration with MacroGenics, Inc. (NASDAQ: MGN
MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
08:30am, Saturday, 10'th Apr 2021
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu
MacroGenics: Pipeline Looks Very Attractive And Somewhat Overlooked
04:02pm, Thursday, 25'th Mar 2021
MacroGenics is a $1.75bn market cap biotech that's pushing the boundaries of drug development.
MacroGenics (MGNX) Stock Jumps 6.6%: Will It Continue to Soar?
04:09am, Monday, 15'th Mar 2021
MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase i
MacroGenics to Participate in Upcoming Investor Conferences
07:30am, Friday, 26'th Feb 2021
ROCKVILLE, MD, Feb. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therape
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q4 2020 Results - Earnings Call Transcript
10:59pm, Thursday, 25'th Feb 2021
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q4 2020 Results - Earnings Call Transcript
MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
04:30pm, Thursday, 18'th Feb 2021
ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therape
MacroGenics Names Federica O'Brien to its Board of Directors
04:30pm, Thursday, 11'th Feb 2021
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
07:30am, Thursday, 11'th Feb 2021
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu
MacroGenics to Participate in Upcoming Investor Conferences
07:30am, Monday, 08'th Feb 2021
ROCKVILLE, MD, Feb. 08, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therape
Why MacroGenics Stock Jumped Today
03:34pm, Monday, 25'th Jan 2021
The company published data from a late-stage study of its promising breast cancer drug.
